Keywords
non-albicans Candida spp.
E-test
minimal inhibitory concentration (MIC)
Abstract
Infections caused by non-albicans Candida spp. are an important medical problem in people from risk groups, e.g. hematooncological patients. The aim of this paper was to analyse the in vitro activity of micafungin against 30 clinical isolates of non-albicans Candida spp. (C. glabrata, C. famata, C. tropicalis, C. inconspicua, C. lusitaniae, C. parapsilosis, C. krusei) by way of the E-test procedure, allowing determination of minimal inhibitory concentration (MIC). Data presented in this paper indicate that most of the studied clinical isolates – 27 (90%) showed sensitivity to micafungin, with MIC values ranging from 0.004 to 2 mg/l, while 3 (10%) isolates, including 2 isolates of C. tropicalis and 1 isolate of C. famata, were resistant to micafungin, with MIC values > 32 mg/l. The MIC50 and MIC90 values of micafungin, defined as MIC inhibited growth of 50% or 90% of the isolates studied, were 0.008 mg/l or 2 mg/l, respectively. In the case of C. glabrata isolates, MICs ranged from 0.004 to 0.016 mg/l, while MIC50 was 0.004 mg/l and MIC90 – 0.008 mg/l. Our data confirm the utility of micafungin for the therapy of the infections caused by non-albicans Candida spp., especially C. glabrata.
References
1. Abuhammour W., Habte-Gaber E.: Newer antifungal agents. Indian. J. Pediatr., 71, 253, 2004. [CrossRef]
2. Andes D.R. et al.: In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother., 52, 3497, 2008. [CrossRef][Web of Science]
3. Arendrup M.C. et al.: European Committee for Antimicrobial Susceptibility Testing (EUCAST). Methods for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EUCAST definitive document EDef 7.2 Revision. March 2012.
4. Baran E., Dyląg M.: Echinokandyny - wielkocząsteczkowe lipopeptydy o aktywności przeciwgrzybiczej. Przegl. Dermatol., 93, 131, 2006.
5. Barry A.L. et al.: Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol., 38, 3457, 2000.
6. Bennett J.E., Izumikawa K., Marr K.A.: Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother., 48, 1773, 2004. [CrossRef]
7. Bormann A.M., Morrison V.A.: Review of the pharmacology and clinical studies of micafungin. Drug Des. Devel. Ther., 29, 295, 2009. [CrossRef]
8. Carter N.J., Keating G.M.: Micafungin: A review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs., 11, 271, 2009.
9. Chandrasekar P.H., Sobel J.D.: Micafungin: A new echinocandin. Clin. Infect. Dis., 42, 1171, 2006. [CrossRef]
10. Chion Ch., Groll A., Walsh T.: New drugs and novel targets for treatment of invasive fungal infections. Oncologist., 2, 120, 2000.
11. Choi H.W. et al.: In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J. Lab. Med., 26, 275, 2006.
12. Dzierżanowska D.: Nowe antybiotyki stosowane w terapii inwazyjnych zakażeń grzybiczych. Zakażenia, 8, 34, 2008.
13. Dzierżanowska D. (2007). Patogeny zakażeń szpitalnych. Bielsko- Biała: α-medicapress.
14. Dzierżanowska D. (2007). Postacie kliniczne zakażeń szpitalnych. Bielsko-Biała: α-medicapress.
15. Eschenauer G., de Pestel D.D., Carver P.L.: Comparison of echinocandin antifungals. Ther. Clin. Risk. Manag., 3, 71, 2007. [CrossRef]
16. Hashimoto S.: Micafungin: A sulfated echinocandin. J. Antibiot., 62, 27, 2009. [CrossRef]
17. Ikeda F. et al.: Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med. Mycol., 47, 145, 2009. [Web of Science] [CrossRef]
18. Joseph J.M., Jain R., Danziger L.H.: Micafungin: A new echinocandin antifungal. Pharmacother., 27, 53, 2007.[CrossRef]
19. Karthaus M., Cornely O.A.: Treatment options in candidaemia. Mycoses, 50, 44, 2007. [Web of Science][CrossRef]
20. Messer S.A. et al.: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol., 44, 324, 2006. [CrossRef]
21. Morris M.I., Villmann M.: Echinocandins in the management of invasive fungal infections. Am. J. Health-Syst. Pharm., 63, 1693, 2006. [CrossRef]
22. Nakai T. et al: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelia forms. Antimicrob. Agents Chemother., 47, 1376, 2003.
23. Nguyen K.T. et al.: Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates. Int. J. Antimicrob. Agents., 35, 80, 2010. [Web of Science] [CrossRef]
24. Oliveira E.R. et al.: Antifungal susceptibility testing of micafungin against Candida glabrata isolates. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 105, 457, 2008.
25. Pappas P.G. et al.: Micafungin versus caspofungin for treatment of candidaemia and other forms of invasive candidiasis. Clin. Infect. Dis., 45, 883, 2007. [CrossRef] [Web of Science]
26. Pfaller M.A. et al.: Wild-type MIC distributions and epidemiological cut off values for the echinocandins and Candida spp. J. Clin. Microbiol., 48, 52, 2010. [Web of Science] [CrossRef]
27. Pfaller M.A. et al.: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: Six years of global surveillance. J. Clin. Microbiol., 46, 150, 2008. [CrossRef] [Web of Science]
28. Pfaller M.A. et al.: Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI - recommended methods. J. Clin. Microbiol., 44, 3533, 2006. [CrossRef]
29. Pfaller M.A. et al.: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol., 46, 2620, 2008. [Web of Science] [CrossRef]
30. Pfeiffer C.D. et al.: Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol., 48, 2373, 2010.[CrossRef]
31. Prasad R., Kappor K.: Multidrug resistance in yeasts Candida. Int. Rev. Cytol., 242, 215, 2005. [CrossRef]
32. Quindos G. et al.: In vitro antifungal activity of micafungin. Rev. Iberoam. Micol., 26, 35, 2009. [CrossRef] [Web of Science]
33. Quindos G., Villar-Vidal M., Eraso E.: Activity of micafungin against Candida biofilms. Rev. Iberoam. Micol., 26, 49, 2009. [Web of Science]
34. Resende M.A. et al.: Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals. Mycopathologia, 162, 39, 2006. [CrossRef]
35. Sucher A.J., Chahine E.B., Balcer H.E.: Echinocandins: The newest class of antifungals. Ann. Pharmacother., 43, 1647, 2009. [CrossRef] [Web of Science]
36. Temesgen Z., Barreto J., Vento S.: Micafungin - the newest echinocandin. Drugs Today, 45, 469, 2009.[CrossRef] [Web of Science]
37. Turner M.S., Drew R.H., Perfect J.R.: Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs., 11, 231, 2006. [CrossRef]
38. White T.C. et al.: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother., 46, 1704, 2002. [CrossRef]
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2015 Authors